The Latest Breaking News from Bristol Myers Squibb

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

In today’s world of increasing disclosures, such as ESG and cybersecurity, the responsibility of the internal audit continues to expand and has become even more critical.

Making health care accessible and equitable is the goal.

'The rich get richer, and the poor get poorer. The same is true for health...The underserved get sicker.'

Bristol's Revlimid took fewer than expected generic hits in the fourth quarter, resulting in a beat and a pop for BMY stock Thursday.

This top health stock stands out with its proven year-over-year earnings growth record, increased earnings estimates and hefty 2.7% dividend.

Most of Bristol Myers' "mature" products delivered commanding third-quarter performances, an analyst said Wednesday as BMY stock rose.

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…